Zobrazeno 1 - 10 of 523 pro vyhledávání: '"Sansó M"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Early-Stage Breast Cancer Detection in Breast Milk.
Autor: Saura C; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Ortiz C; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Matito J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Arenas EJ; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Suñol A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Martín Á; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Córdoba O; Servicio Obstetricia y Ginecología, Hospital Universitari Son Espases (HUSE), Palma, Spain.; Institut de Investigació de les Illes Balears (IdISBa), Palma, Spain.; Universitat de les Illes Balears (UIB), Palma, Spain., Martínez-Sabadell A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., García-Ruiz I; Obstetrics Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Miranda I; Radiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Morales-Comas C; Gynecology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Carrasco E; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Viaplana C; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Peg V; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Pathology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.; Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain., Nuciforo P; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Bayó-Puxan N; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Gonzalez-Medina A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Miquel JM; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Gómez-Rey M; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Villacampa G; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Arévalo S; Obstetrics Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Espinosa-Bravo M; Gynecology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Balmaña J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Dienstmann R; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Arribas J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.; Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.; Hospital del Mar Research Institute (HMRI), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Tabernero J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; University of Vic-Central University of Catalonia (UVic-UCC), Barcelona, VIC, Spain.; IOB Institute of Oncology, Quiron Group, Barcelona, Spain., Vivancos A; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain., Sansó M; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus. Barcelona, Spain.
Publikováno v: Cancer discovery [Cancer Discov] 2023 Oct 05; Vol. 13 (10), pp. 2180-2191.
Zobrazit plný text záznamu
4
Akademický článek
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.
Autor: Carbonell C; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain., Frigola J; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain., Pardo N; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain., Callejo A; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain., Iranzo P; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain., Valdivia A; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain., Priano I; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain., Cedrés S; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain., Martinez-Marti A; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain., Navarro A; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain., Lenza L; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain., Soleda M; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain., Gonzalo-Ruiz J; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain., Vivancos A; Cancer Genomics Laboratory, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain., Sansó M; Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, Spain., Carcereny E; Medical Oncology Department, Catalan Institute of Oncology Badalona, Hospital Universitari Germans Trias i Pujol, Badalona Applied Research Group in Oncology, Institut Germans Trias i Pujol, Barcelona, Spain., Morán T; Medical Oncology Department, Catalan Institute of Oncology Badalona, Hospital Universitari Germans Trias i Pujol, Badalona Applied Research Group in Oncology, Institut Germans Trias i Pujol, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Spain., Amat R; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain., Felip E; Thoracic Cancers Translational Genomics Unit, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Clinical Research Department, Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, Spain.; Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Spain.
Publikováno v: Molecular oncology [Mol Oncol] 2023 May; Vol. 17 (5), pp. 779-791. Date of Electronic Publication: 2023 Mar 21.
Zobrazit plný text záznamu
5
Akademický článek
Distinct Cdk9-phosphatase switches act at the beginning and end of elongation by RNA polymerase II.
Autor: Parua PK; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, USA., Kalan S; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, USA., Benjamin B; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, USA., Sansó M; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, USA., Fisher RP; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, USA. Robert.fisher@mssm.edu.
Publikováno v: Nature communications [Nat Commun] 2020 Aug 28; Vol. 11 (1), pp. 4338. Date of Electronic Publication: 2020 Aug 28.
Zobrazit plný text záznamu
6
Akademický článek
Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer.
Autor: Martinez-Marti A; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Autonomous University of Barcelona (UAB), Barcelona, Spain., Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; University of Vic (UVIC) Central University of Catalonia (UCC), Barcelona, Spain., Mancuso FM; Cancer Genomics Group, VHIO, Barcelona, Spain., Caratú G; Cancer Genomics Group, VHIO, Barcelona, Spain., Matito J; Cancer Genomics Group, VHIO, Barcelona, Spain., Nuciforo P; Molecular Oncology Group, VHIO, Barcelona, Spain., Sansano I; Pathology Department, VHUH, Barcelona, Spain., Diaz-Mejia N; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Cedrés S; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Callejo A; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Iranzo P; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Pardo N; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Miquel JM; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Navarro A; Department of Medical Oncology, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Vivancos A; Cancer Genomics Group, VHIO, Barcelona, Spain., Sansó M; Cancer Genomics Group, VHIO, Barcelona, Spain. miriam.sanso@ssib.es.; Balearic Islands Health Research Institute (IdISBa), Palma de Mallorca, Spain. miriam.sanso@ssib.es.; Genomics for Precision Oncology Group, Health Research Institute of the Balearic Islands (IdISBa), University Hospital Son Espases (HUSE), Palma de Mallorca, Spain. miriam.sanso@ssib.es.
Publikováno v: British journal of cancer [Br J Cancer] 2021 Nov; Vol. 125 (11), pp. 1561-1569. Date of Electronic Publication: 2021 Oct 01.
Zobrazit plný text záznamu
7
Report
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer.
Autor: Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain., Sansó M; Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Oncology and Hematology, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain., Chic N; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain., Martínez D; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain., González-Farré B; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Pathology, Hospital Clínic de Barcelona, Barcelona, Spain., Sanfeliu E; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Pathology, Hospital Clínic de Barcelona, Barcelona, Spain., Ghiglione L; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain., Carcelero E; Department of Pharmacy, Hospital Clínic of Barcelona, Barcelona, Spain., Garcia-Corbacho J; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain., Sánchez M; Department of Radiology, Hospital Clínic of Barcelona, Barcelona, Spain., Soy D; Department of Pharmacy, Hospital Clínic of Barcelona, Barcelona, Spain., Jares P; Molecular Biology Core, Hospital Clinic of Barcelona, Barcelona, Spain., Peg V; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Medical Oncology Service, Barcelona, Spain., Saura C; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Medical Oncology Service, Barcelona, Spain.; SOLTI Cooperative Group, Barcelona, Spain.; Department of Oncology, Institut Oncològic Baselga (IOB) Institute of Oncology, Quironsalud Group, Barcelona, Spain., Muñoz M; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain.; Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; SOLTI Cooperative Group, Barcelona, Spain.; Department of Oncology, Institut Oncològic Baselga (IOB) Institute of Oncology, Quironsalud Group, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain., Vivancos A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Publikováno v: Frontiers in oncology [Front Oncol] 2021 Sep 20; Vol. 11, pp. 710596. Date of Electronic Publication: 2021 Sep 20 (Print Publication: 2021).
Zobrazit plný text záznamu
8
Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II
Autor: Shokat, Kevan, Larochelle, S, Amat, R, Glover-Cutter, K, Sansó, M, Zhang, C, Allen, JJ, Shokat, KM, Bentley, DL, Fisher, RP
Publikováno v: Shokat, Kevan; Larochelle, S; Amat, R; Glover-Cutter, K; Sansó, M; Zhang, C; et al.(2012). Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/6cb7772k
Promoter-proximal pausing by RNA polymerase II (Pol II) ensures gene-specific regulation and RNA quality control. Structural considerations suggested a requirement for initiation-factor eviction in elongation-factor engagement and pausing of transcri
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::431ee7f54b23accc716beaf9c917489b
http://www.escholarship.org/uc/item/6cb7772k
Zobrazit plný text záznamu
9
A Positive Feedback Loop Links Opposing Functions of P-TEFb/Cdk9 and Histone H2B Ubiquitylation to Regulate Transcript Elongation in Fission Yeast
Autor: Shokat, Kevan, Sansó, M, Lee, KM, Viladevall, L, Jacques, PE, Pagé, V, Nagy, S, Racine, A, St, CV, Zhang, C, Shokat, KM
Publikováno v: Shokat, Kevan; Sansó, M; Lee, KM; Viladevall, L; Jacques, PE; Pagé, V; et al.(2012). A Positive Feedback Loop Links Opposing Functions of P-TEFb/Cdk9 and Histone H2B Ubiquitylation to Regulate Transcript Elongation in Fission Yeast. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/84v2g0pn
Transcript elongation by RNA polymerase II (RNAPII) is accompanied by conserved patterns of histone modification. Whereas histone modifications have established roles in transcription initiation, their functions during elongation are not understood.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::994d9c8cc1c1a6187f19b30fb864a939
http://www.escholarship.org/uc/item/84v2g0pn
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje